Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Allenaâs second product candidate, ALLN-346, is in preclinical development for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders. Source
No articles found.
Virtuoso Surgical, Inc. was born out of a collaborative research effort developing...
Virtuoso Surgical, Inc. was born out of a colla...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
We are a clinical-stage immuno-oncology company specializing in the development an...
We are a clinical-stage immuno-oncology company...
Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company ded...
Arbutus Biopharma is a publicly-traded (NASDAQ:...
Join the National Investor Network and get the latest information with your interests in mind.